Canine N-terminal pro-B-type natriuretic peptide (cNT-proBNP): It is a marker of cardiac load in dogs. Its levels increase in cases such as increased cardiac load after exercise, valvular heart disease, and heart failure.
Reference Recommendations for NEW-TEST Canine NT-proBNP: When a dog has valvular disease (MMVD), a concentration of 800-2500 nmol/L suggests that the dog's MMVD may be in the b1-b2 stage. Most dogs may show no obvious symptoms. A concentration of 2500-4500 nmol/L (b2-C stage) indicates that the dog has a high risk of developing heart failure (HF) within 6-12 months. It is recommended to perform further echocardiogram examinations or annual physical examinations. When the concentration is > 4500 nmol/L, the likelihood of heart failure is extremely high.
This product utilizes fluorescence immunochromatography to quantitatively detect the cNT-proBNP content in serum or plasma. The basic principle is as follows: T and C lines are respectively marked on the nitrocellulose membrane. The T line is coated with an antibody a that specifically recognizes cNT-proBNP. The binding pad is sprayed with another fluorescent nano-material-labeled antibody b that specifically recognizes cNT-proBNP. The cNT-proBNP in the sample first combines with the nano-material-labeled antibody b to form a complex. Then, through chromatography upwards, the complex moves upwards and binds to T line antibody a, forming a sandwich structure. When the test strip is irradiated by excitation light, the nanomaterial emits a fluorescent signal, and the intensity of this signal is positively correlated with the concentration of cNT-proBNP in the sample.
Since its establishment, our factory has been develop first world class products with adhering the principle
of quality first. Our products have gained excellent reputation in the industry and valuabletrusty among new and old customers..